The results of the PRESTOCON preclinical trial have demonstrated that Panax ginseng and Gingko biloba extracts have a well-documented safety profile and are well tolerated for the treatment of moderate-to-severe disease.
In addition, the trial provided useful insights into the application of Panax ginseng (G115) and Gingko biloba (GK501) as novel and natural therapeutic intervention for the treatment of cognitive-related diseases.
These findings support the idea that the combination may become a valid and safe therapeutic intervention in the treatment of neurological disorders.
To download the full article, click on the link below:
- Brands
- Services
- About SFI services
- Access:
- Medical Marketing
- Product Development
- Research & Development
- Regulatory Affairs
- Build:
- Manufacturing Capabilities
- Sell:
- SFI Selling Platforms & Channel Brands
- Global Distribution Network
- Case Studies
- About SFI
